Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Homophilic binding of mouse monoclonal antibodies against GD3 ganglioside.

Chapman PB, Yuasa H, Houghton AN.

J Immunol. 1990 Aug 1;145(3):891-8.

PMID:
1695649
2.

Characterization of an Ig VH idiotope that results in specific homophilic binding and increased avidity for antigen.

Yan X, Evans SV, Kaminki MJ, Gillies SD, Reisfeld RA, Houghton AN, Chapman PB.

J Immunol. 1996 Aug 15;157(4):1582-8.

PMID:
8759742
3.

The role of homophilic binding in anti-tumor antibody R24 recognition of molecular surfaces. Demonstration of an intermolecular beta-sheet interaction between vh domains.

Kaminski MJ, MacKenzie CR, Mooibroek MJ, Dahms TE, Hirama T, Houghton AN, Chapman PB, Evans SV.

J Biol Chem. 1999 Feb 26;274(9):5597-604.

5.

Mapping effector functions of a monoclonal antibody to GD3 by characterization of a mouse-human chimeric antibody.

Chapman PB, Gillies SD, Houghton AN, Reilly RM.

Cancer Immunol Immunother. 1994 Sep;39(3):198-204.

PMID:
7522964
6.

Immune and nonimmune effector functions of IgG3 mouse monoclonal antibody R24 detecting the disialoganglioside GD3 on the surface of melanoma cells.

Welt S, Carswell EA, Vogel CW, Oettgen HF, Old LJ.

Clin Immunol Immunopathol. 1987 Nov;45(2):214-29.

PMID:
3665201
7.

The idiotype (Id) cascade in mice elicited the production of anti-R24 Id and anti-anti-Id monoclonal antibodies with antitumor and protective activity against human melanoma.

Ramos AS, Parise CB, Travassos LR, Han SW, de Campos-Lima PO, de Moraes JZ.

Cancer Sci. 2011 Jan;102(1):64-70. doi: 10.1111/j.1349-7006.2010.01771.x. Epub 2010 Nov 10.

8.

Monoclonal antibody R24 distinguishes between different N-acetyl- and N-glycolylneuraminic acid derivatives of ganglioside GD3.

Tai T, Kawashima I, Furukawa K, Lloyd KO.

Arch Biochem Biophys. 1988 Jan;260(1):51-5.

PMID:
2449128
9.

Immunocytochemical study on internalization of anti-carbohydrate monoclonal antibodies.

Kusano A, Ohta S, Shitara K, Hanai N.

Anticancer Res. 1993 Nov-Dec;13(6A):2207-12.

PMID:
8297135
10.

Recombinant antibodies against ganglioside expressed on tumor cells.

Hanai N, Nakamura K, Shitara K.

Cancer Chemother Pharmacol. 2000;46 Suppl:S13-7.

PMID:
10950141
11.

GD3 ganglioside antibody augments tumoricidal capacity of canine blood mononuclear cells by induction of interleukin 12.

Helfand SC, Dickerson EB, Munson KL, Padilla ML.

Cancer Res. 1999 Jul 1;59(13):3119-27.

12.
13.

Production and molecular characterization of clinical phase i anti-melanoma mouse IgG3 monoclonal antibody R24.

Kemminer SE, Conradt HS, Nimtz M, Sagi D, Peter-Katalinić J, Diekmann O, Drmić I, Müthing J.

Biotechnol Prog. 2001 Sep-Oct;17(5):809-21.

PMID:
11587568
14.

R24 anti-GD3 ganglioside antibody can induce costimulation and prevent the induction of alloantigen-specific T cell clonal anergy.

Boussiotis VA, Pardo NA, Collins H, Houghton A, Ritz J, Nadler LM, Soiffer RJ.

Eur J Immunol. 1996 Sep;26(9):2149-54.

PMID:
8814260
15.
17.

Treatment with high dose mouse monoclonal (anti-GD3) antibody R24 in patients with metastatic melanoma.

Bajorin DF, Chapman PB, Wong GY, Cody BV, Cordon-Cardo C, Dantes L, Templeton MA, Scheinberg D, Oettgen HF, Houghton AN.

Melanoma Res. 1992 Dec;2(5-6):355-62.

PMID:
1292783
18.
19.

Anti-melanoma effects of R24, a monoclonal antibody against GD3 ganglioside.

Nasi ML, Meyers M, Livingston PO, Houghton AN, Chapman PB.

Melanoma Res. 1997 Aug;7 Suppl 2:S155-62. Review.

PMID:
9578432
20.

Antiidiotypic activity in the IgM fractions of mixed cryoglobulins.

Geltner D, Franklin EC, Frangione B.

J Immunol. 1980 Oct;125(4):1530-5.

PMID:
6774023

Supplemental Content

Support Center